Crispr Therapeutics shares tumble after significant earnings miss
In recent activity disclosed by Veru Inc. (NASDAQ:VERU), Director Michael L. Rankowitz has acquired shares of the company’s common stock, totaling approximately $84,350. The purchases occurred over two days, on February 18 and 19, 2025, with stock prices ranging from $0.5503 to $0.5833 per share. The timing appears strategic, as the stock has surged 14% in the past week, though it remains well below analyst targets ranging from $3 to $5. InvestingPro data reveals comprehensive insider trading patterns and 14 additional key insights for this $83M market cap company.
The acquisitions involved 95,279 shares on February 18 and an additional 54,721 shares on February 19, bringing Rankowitz’s total holdings to 250,000 shares following these transactions. These purchases reflect a significant increase in Rankowitz’s direct ownership in the pharmaceutical company, which specializes in life sciences. According to InvestingPro analysis, while the company maintains a weak financial health score, it holds more cash than debt and shows a high shareholder yield, factors that may have influenced the director’s investment decision.
In other recent news, Veru Inc. reported its fiscal first quarter 2025 earnings, which showed a net loss per share of $0.06, outperforming the forecasted loss of $0.08. The company’s revenue also exceeded expectations, reaching $3.2 million compared to the anticipated $3 million. Despite these positive financial results, Veru’s stock experienced a decline, reflecting ongoing investor concerns. The company highlighted its strategic shift towards drug development, including the sale of its FC2 female condom business, which generated $16.4 million in net proceeds. This move aligns with Veru’s focus on advancing its clinical-stage drug candidates, Enobasarm and Cebizobulin.
Analysts at Oppenheimer adjusted their outlook on Veru, reducing the stock’s price target from $5 to $4 while maintaining an Outperform rating. This decision followed Veru’s earnings report and updates on its ongoing Phase 2b study of enobosarm, which is expected to yield results next quarter. Oppenheimer anticipates that the upcoming data will demonstrate enobosarm’s effectiveness in maintaining muscle mass and preventing fat regain after GLP-1 therapy discontinuation. The financial status of the company, particularly its cash reserves, was noted as a point of consideration for investors. These developments underscore Veru’s efforts to position itself as a leader in pharmaceutical advancements, particularly in weight loss therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.